Mates
Abraham Mates, Givat Shmuel IL
Patent application number | Description | Published |
---|---|---|
20090005704 | Specimen Collection Container - A liquid specimen collection container is described that includes a cup which has a base, an edge portion, and a sidewall extending from the base to the edge portion. The container additionally includes a lid disposed on the edge portion. The lid has a recessed portion which forms a protrusion extending downward into the cup. The container also includes a flexible extraction tube permanently affixed to the bottom of the protrusion with the tube reaching the base of the cup. The container further typically includes a transfer means positioned inside the recessed portion of the lid, the transfer means in liquid communication with the flexible tube. The transfer means assists in transferring liquid from the container to another vessel. A system is also described that includes the above specimen collection container and a vessel into which collected liquid is transferred from the container. | 01-01-2009 |
John W. Mates, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20090171163 | MODULAR MEDICAL DEVICES - Apparatus and method provide for forming a modular medical device by selecting a combination of medical device modules and combining them to form the modular medical device, for example by plugging them together or into a common bus. In one embodiment, the modules are selected from a group of modules adapted to be used in combination to perform one or more medical functions for a particular patient. In one embodiment at least one module is adapted to store data, at least one module is adapted to perform a communication function, at least one module is used to control the medical device, at least one module is adapted to provide a sense function, and at least one module provides energy to the medical device. In another embodiment the modular medical devices may be rented or sold to patients, or prescribed by physicians and covered by medical insurance. | 07-02-2009 |
20090313694 | GENERATING A CHALLENGE RESPONSE IMAGE INCLUDING A RECOGNIZABLE IMAGE - Provided are a method, system, and article of manufacture for generating a challenge response image including a recognizable image. A challenge image is generated including random elements and a recognizable image. The challenge image is transmitted to a recipient. Recipient input associated with the transmitted challenge image is received. A determination is made as to whether the received recipient input matches a descriptor associated with the recognizable image in the challenge image. Indication is made that the recipient correctly identified the recognizable image. | 12-17-2009 |
Lajos Mates, Berlin DE
Patent application number | Description | Published |
---|---|---|
20110117072 | HYPERACTIVE VARIANTS OF THE TRANSPOSASE PROTEIN OF THE TRANSPOSON SYSTEM SLEEPING BEAUTY - The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed. | 05-19-2011 |
Russell F. Mates, Clarks Summit, PA US
Patent application number | Description | Published |
---|---|---|
20130265169 | Eyewear Device Configured To Track Head Movement - Disclosed is an eyewear device that includes eyeglass lenses and an eyewear frame configured to hold the eyeglass lenses. According to one example, the eyeglass frame may include a number of sensors configured to determine a position of the eyewear frame. The eyewear device may also include a transceiver configured to receive periodic radio frequency (RF) signals from a remote device and to transmit corresponding RF feedback signals to the remote device responsive to the received periodic RF signal and at least one operation indicator configured to initiate operation when the eyewear frame is moved outside of a predetermined position. | 10-10-2013 |
Sharon Mates, New York, NY US
Patent application number | Description | Published |
---|---|---|
20100087450 | ORGANIC COMPOUNDS - The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophylaxis of narcolepsy. | 04-08-2010 |
20100323997 | NOVEL USES - The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction. | 12-23-2010 |
20110071080 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 03-24-2011 |
20130202692 | ORGANIC COMPOUNDS - The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT | 08-08-2013 |
20140050783 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 02-20-2014 |
20150038519 | ORGANIC COMPOUNDS - The invention provides a new method of treating diseases or conditions characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, depression, and cognitive impairment of schizophrenia, comprising administering an effective amount of a 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one to a patient in need thereof. | 02-05-2015 |
20150072964 | NOVEL METHODS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders. | 03-12-2015 |
20150079172 | ORGANIC COMPOUNDS - The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT | 03-19-2015 |
20150080404 | NOVEL COMPOSITIONS AND METHODS - The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia. | 03-19-2015 |